{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:17:54Z","timestamp":1747185474770,"version":"3.40.5"},"reference-count":59,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>At present, surgery is still the gold standard for the local treatment of renal cancer. Nonetheless, in several clinical scenarios, stereotactic body radiation therapy (SBRT) also known as stereotactic ablative body radiotherapy (SABR) is emerging as a highly effective ablative technique in fragile patients and those with significant comorbidities, as well as in cases where percutaneous therapy (cryoablation or radiofrequency) is not viable. However, considering the intrinsic radioresistance of renal tumors, the optimal treatment schemes have not been established. In oligometastatic patients, it has been reported that the control of the oligometastases can be a potentially curable approach. Being a technique than can be administered exclusively or in combination with systemic therapy, treatment individualization based on patient characteristics is key. Another scenario under investigation is oligoprogression, where SBRT offers the possibility of delaying further lines of systemic therapy by eliminating subclones of resistant tumor with ablative doses, with the additional opportunity of stimulating the immune system (immunomodulatory role). In this review, we have conducted an analysis of recently published studies that test the role of this technique in different clinical scenarios of this disease. We have found promising results that make SBRT a potent therapeutic approach with low toxicity. We also comment on ongoing studies that will generate the necessary evidence needed for the implementation of this technique in our daily clinical practice.<\/jats:p>","DOI":"10.1111\/iju.15156","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T03:02:04Z","timestamp":1675738924000},"page":"437-445","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Stereotactic body radiation therapy for kidney cancer. Where do we stand?"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0130-321X","authenticated-orcid":false,"given":"Paloma","family":"Sosa\u2010Fajardo","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Instituto de Biomedicina de Sevilla (IBIS\/CSIC\/CIBERONC), University Hospital Virgen del Rocio Universidad de Sevilla  Sevilla Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas M.","family":"Blanco\u2010Suarez","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Instituto de Biomedicina de Sevilla (IBIS\/CSIC\/CIBERONC), University Hospital Virgen del Rocio Universidad de Sevilla  Sevilla Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Pineda\u2010Mungu\u00eda","sequence":"additional","affiliation":[{"name":"Urology Department Hospital El Bierzo  Ponferrada Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luz","family":"Rub\u00ed\u2010Olea","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department University Regional Hospital  M\u00e1laga Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Peleteiro\u2010Higuero","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department University Hospital Complex of Santiago de Compostela  Santiago de Compostela Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Gajate","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Ramon y Cajal Hospital IRYCIS  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Zafra\u2010Mart\u00edn","sequence":"additional","affiliation":[{"name":"Group of Translational Research in Cancer Immunotherapy, Health and Medical Research Centre (CIMES), Institute of Biomedical Research in Malaga (IBIMA) University of Malaga (UMA)  Malaga Spain"},{"name":"Department of Radiation Oncology Virgen de la Victoria University Hospital  Malaga Spain"},{"name":"Faculty of Medicine University of Malaga (UMA)  Malaga Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre University of Melbourne  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Bossi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology University Hospitals Gasthuisberg  Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4077-0507","authenticated-orcid":false,"given":"Fernando","family":"L\u00f3pez\u2010Campos","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Ramon y Cajal Hospital IRYCIS  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Cou\u00f1ago","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, GenesisCare Madrid Clinical Director, San Francisco de Asis and La Milagrosa Hospitals, National Chair of Research and Clinical Trials GenesisCare  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70569-2"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-017-1185-y"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.08.030"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11550.x"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2019.10.001"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/1533033818822329"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13811"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.08.044"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.07.043"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.12.018"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-019-0531-z"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2016.04.002"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4916-2"},{"key":"e_1_2_10_16_1","unstructured":"MotzerRJ Memorial Sloan Kettering cancer center \u00de JonaschE AgarwalN AlvaA BaineM et\u00a0al.NCCN guidelines version 4.2022 kidney cancer continue NCCN guidelines panel disclosures.2021[cited 2022 Mar 15]. Available from:https:\/\/www.nccn.org\/home\/member\u2010"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.16.2"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2020.01.002"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.04.038"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.08.036"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.08.010"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2019.11.009"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.03.014"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00046-X"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyp167"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32487-5"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2020.1770601"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.05.007"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00528-3"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2019.100161"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.07.023"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2018.08.049"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.01.032"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.10.108"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2015.05.004"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-015-0528-z"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.11.026"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e31825d52b2"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000110610.61545.ae"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.06.009"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.6963"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70235-9"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66954-1"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.03.062"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-022-02793-z"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-021-10131-w"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.04.008"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25564"},{"key":"e_1_2_10_49_1","first-page":"97","article-title":"Survival after combining stereotactic body radiation therapy and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma","volume":"11","author":"Liu Y","year":"2021","journal-title":"Front Oncol"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.07.026"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000535"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09895.x"},{"key":"e_1_2_10_53_1","first-page":"1","article-title":"Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial","volume":"12","author":"Wolf K","year":"2017","journal-title":"Radiat Oncol"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-021-01937-9"},{"key":"e_1_2_10_55_1","doi-asserted-by":"crossref","unstructured":"HammersHJ VonmerveldtD AhnC NadalRM DrakeCG FolkertMR et\u00a0al.Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC).2020;38(6_suppl):614.","DOI":"10.1200\/JCO.2020.38.6_suppl.614"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.09.016"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.12.006"},{"key":"e_1_2_10_58_1","unstructured":"Study assessing stereotactic radiotherapy in therapeutic strategy of oligoprogressive renal cell carcinoma metastases. ClinicalTrials.gov. [cited 2022 Dec 2]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04299646"},{"key":"e_1_2_10_59_1","unstructured":"UCDCC#272: IL\u20102 radiotherapy and pembrolizumab in patients refractory to checkpoint blockade. ClinicalTrials.gov. [cited 2022 Dec 2]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03474497"},{"key":"e_1_2_10_60_1","unstructured":"Study evaluating the safety and the efficacy of combination of atezolizumab tiragolumab and and stereotactic body radiation therapy in patients with oligometastatic multiorgan (IMMUNOs\u2010SBRT). ClinicalTrials.gov. [cited 2022 Dec 2]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05259319"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.15156","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/iju.15156","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.15156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T14:35:56Z","timestamp":1692455756000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.15156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/iju.15156"],"URL":"https:\/\/doi.org\/10.1111\/iju.15156","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"type":"print","value":"0919-8172"},{"type":"electronic","value":"1442-2042"}],"subject":[],"published":{"date-parts":[[2023,2,6]]},"assertion":[{"value":"2022-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}